コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 debilitating, and difficult to treat in the immunocompromised host.
2 increasingly recognized as pathogenic in the immunocompromised host.
3 tment of this oral infection in the severely immunocompromised host.
4 atment of gastrointestinal infections in the immunocompromised host.
5 regarding gastrointestinal infections in the immunocompromised host.
6 hat causes P. carinii pneumonia (PCP) in the immunocompromised host.
7 fungal pathogen that causes pneumonia in the immunocompromised host.
8 expanded pool of EBV-infected B cells in the immunocompromised host.
9 al benefits when used for prophylaxis in the immunocompromised host.
10 ng cause of human disease, especially in the immunocompromised host.
11 ly contributes to disease progression in the immunocompromised host.
12 nosis and management of CMV infection in the immunocompromised host.
13 trpD mutant was essentially avirulent in an immunocompromised host.
14 e treatment of invasive aspergillosis in the immunocompromised host.
15 expressing the LMP1 deletion variant in the immunocompromised host.
16 exudative pleural effusion, especially in an immunocompromised host.
17 domain of LMP1 at the molecular level in an immunocompromised host.
18 ergillosis is a lethal mold infection in the immunocompromised host.
19 ) pathogens within an enlarging populationof immunocompromised host.
20 5-month infection in an IL12Rbeta1-deficient immunocompromised host.
21 for inciting vaccine strain infection in an immunocompromised host.
22 thogenesis of pulmonary aspergillosis in the immunocompromised host.
23 genesis of HCMV infection and disease in the immunocompromised host.
24 s (HCMV) causes significant morbidity in the immunocompromised host.
25 n cause lethal invasive aspergillosis in the immunocompromised host.
26 growth advantage to intracellular Mtb in an immunocompromised host.
27 hreatening invasive fungal infections in the immunocompromised host.
28 s, resulting in a varied pathogenesis in the immunocompromised host.
29 issue source caused by Y. regensburgei in an immunocompromised host.
30 acute and chronic pulmonary infection in the immunocompromised host.
31 ts into the evolution of norovirus within an immunocompromised host.
32 ife-threatening disease in the fetus and the immunocompromised host.
33 with lower respiratory tract disease in the immunocompromised host.
34 tis, keratitis, and severe infections in the immunocompromised host.
35 -threatening opportunistic infections in the immunocompromised host.
36 ns to restore virus-specific immunity in the immunocompromised host.
37 atment of gastrointestinal infections in the immunocompromised host.
38 ey could serve as opportunistic pathogens in immunocompromised hosts.
39 ly presents as an opportunistic infection in immunocompromised hosts.
40 ts also infect the gastrointestinal tract in immunocompromised hosts.
41 nary disease exacerbations, and pneumonia in immunocompromised hosts.
42 s against microbial infection in healthy and immunocompromised hosts.
43 e of chronic respiratory tract infections in immunocompromised hosts.
44 edominant agent of invasive aspergillosis in immunocompromised hosts.
45 en that causes invasive pulmonary disease in immunocompromised hosts.
46 toxins or "correct" hypogammaglobulinemia in immunocompromised hosts.
47 s adherent to the epithelium in the lungs of immunocompromised hosts.
48 st defense against invasive aspergillosis in immunocompromised hosts.
49 umocystis carinii causes severe pneumonia in immunocompromised hosts.
50 systems and could contribute to virulence in immunocompromised hosts.
51 n the control of gammaherpesvirus latency in immunocompromised hosts.
52 and treats EBV-driven lymphoproliferation in immunocompromised hosts.
53 better identify aberrant responses to CMV in immunocompromised hosts.
54 ng high levels of latently infected cells in immunocompromised hosts.
55 unodeficiency virus or occasionally in other immunocompromised hosts.
56 tant CD4(+) T cells do not induce colitis in immunocompromised hosts.
57 sis is a common and devastating pneumonia in immunocompromised hosts.
58 the transfer of allogeneic bone marrow into immunocompromised hosts.
59 vere infections in hospitalized patients and immunocompromised hosts.
60 r the inability to eradicate the organism in immunocompromised hosts.
61 pathological picture when transplanted into immunocompromised hosts.
62 ost microbes that cause disease primarily in immunocompromised hosts.
63 ency virus (HIV)-infected patients and other immunocompromised hosts.
64 e of morbidity and mortality in neonates and immunocompromised hosts.
65 d with several malignancies, particularly in immunocompromised hosts.
66 a fungal pathogen that causes meningitis in immunocompromised hosts.
67 ion in newborns, pregnant females, and other immunocompromised hosts.
68 ng HPV-associated malignancies in normal and immunocompromised hosts.
69 nella pneumonia, and occurs predominantly in immunocompromised hosts.
70 ng protozoan parasite of immunocompetent and immunocompromised hosts.
71 ificant source of morbidity and mortality in immunocompromised hosts.
72 ally fail to cure cryptococcal infections in immunocompromised hosts.
73 eukaryotic organism that causes pneumonia in immunocompromised hosts.
74 etal medicine, and specialties that care for immunocompromised hosts.
75 oying phage cocktails in immunocompetent and immunocompromised hosts.
76 pulmonary and invasive mold infections among immunocompromised hosts.
77 e human disease, particularly in elderly and immunocompromised hosts.
78 ngal pathogens associated with infections in immunocompromised hosts.
79 its use as an adjunct for severe disease in immunocompromised hosts.
80 ociated with numerous cancers, especially in immunocompromised hosts.
81 the immune system such as might be found in immunocompromised hosts.
82 Toxoplasma gondii can be life-threatening in immunocompromised hosts.
83 life-threatening disease that affects mainly immunocompromised hosts.
84 recently revised definitions for classically immunocompromised hosts.
85 that causes Pneumocystis pneumonia (PCP) in immunocompromised hosts.
86 ilms, which facilitate chronic infections in immunocompromised hosts.
87 r causing lung and soft tissue infections in immunocompromised hosts.
88 emerging application of booster vaccines in immunocompromised hosts.
89 gement of persistent SARS-CoV-2 infection in immunocompromised hosts.
90 sed by these organisms have been reported in immunocompromised hosts.
91 mmunocompetent hosts and invasive disease in immunocompromised hosts.
92 l disease during waterborne epidemics and in immunocompromised hosts.
93 trategy for prophylaxis in vulnerable and/or immunocompromised hosts.
94 -infection-related fatalities, especially in immunocompromised hosts.
95 lance is needed to prevent CRE infections in immunocompromised hosts.
96 requency in the past decade, particularly in immunocompromised hosts.
97 vidualized antifungal therapy/prophylaxis in immunocompromised hosts.
98 e range of serious infections, especially in immunocompromised hosts.
99 lytic replication that can be pathogenic in immunocompromised hosts.
100 cause fatal disease, especially lymphoma, in immunocompromised hosts.
101 a high mortality with a rising prevalence in immunocompromised hosts.
102 y common pathogen of humans, particularly in immunocompromised hosts.
103 ibuted deep mycosis that affects healthy and immunocompromised hosts.
104 s of opportunistic infections in healthy and immunocompromised hosts.
105 enza viruses, especially in seriously ill or immunocompromised hosts.
106 hanced survival after adoptive transfer into immunocompromised hosts.
107 bacterium that causes systemic infections in immunocompromised hosts.
108 infections (IFI) remain a serious threat to immunocompromised hosts.
109 auses substantial morbidity and mortality in immunocompromised hosts.
110 h obstructive lung disease, and pneumonia in immunocompromised hosts.
111 gal pathogens that cause severe pneumonia in immunocompromised hosts.
112 gus, can cause lethal invasive infections in immunocompromised hosts.
113 incidence of lymphoproliferative disease in immunocompromised hosts.
114 g asthma exacerbations and severe disease in immunocompromised hosts.
115 stemic and often life-threatening disease in immunocompromised hosts.
116 e more severe and more difficult to treat in immunocompromised hosts.
117 ctive immune mechanisms needed to protect an immunocompromised host against an opportunistic infectio
118 s substantial morbidity and mortality in the immunocompromised host and has no approved therapy.
120 nd disseminated diseases, particularly among immunocompromised hosts and critically ill adults as wel
121 pment of antiviral resistance, especially in immunocompromised hosts and critically ill patients.
124 aeruginosa causes a variety of infections in immunocompromised hosts and in individuals with cystic f
125 g the pathogenesis of T. gondii infection in immunocompromised hosts and in the design of anti-T. gon
126 le IFD were primarily designed for classical immunocompromised hosts and may therefore not be ideal f
127 stic pathogens associated with infections in immunocompromised hosts and patients with cystic fibrosi
128 l receptors can improve treatment outcome in immunocompromised hosts and reduce the chance that patho
129 y the pathogenicity of avirulent microbes in immunocompromised hosts and the lack of pathogenicity of
130 C. albicans causes serious disease only in immunocompromised hosts and therefore the ability to imm
131 nfections are increasing, particularly among immunocompromised hosts, and a rapid diagnosis is essent
132 ajor cause of infection in normal as well as immunocompromised hosts, and the increasing prevalence o
134 xclusively in opportunistic settings--in the immunocompromised host--and these infections are the foc
136 of infection and how this is altered in the immunocompromised host are key goals for comprehension o
137 to cause a spectrum of disease states in the immunocompromised host are questions of significant biol
141 ommon microorganisms and septic arthritis in immunocompromised hosts are other noteworthy topics in t
144 icable emerging pathogens, and infections in immunocompromised hosts are some examples of current pro
145 ease because of an ever-increasing number of immunocompromised hosts as a result of HIV infection and
146 luenza virus infection is complicated in the immunocompromised host because of suboptimal responses t
147 tii infection can cause diseases in not only immunocompromised hosts but also immunocompetent individ
148 umigatus causes invasive disease in severely immunocompromised hosts but is readily cleared when host
149 uses can cause high mortality, especially in immunocompromised hosts, but the impact of human metapne
155 CMV)-specific CD8(+) T lymphocytes (CTLs) in immunocompromised hosts demonstrate a central role for v
156 respiratory infection in humans; however, in immunocompromised hosts, disseminated infection can occu
158 P multocida is a rare cause of infections in immunocompromised hosts, epidemiologically linked to exp
162 %) patients had no immunocompromise; 6 of 24 immunocompromised hosts had idiopathic CD4 lymphopenia,
163 wever, its role as a respiratory pathogen in immunocompromised hosts has been infrequently recognized
166 nts with HSV meningitis rapidly improve, but immunocompromised hosts have more neurologic sequelae an
167 cant morbidity, particularly in neonates and immunocompromised hosts, highlighting the need for novel
168 l known that C. neoformans generally affects immunocompromised hosts; however, C. gattii infection ca
170 us infection is an emerging challenge in the immunocompromised host, in whom it may be asymptomatic o
171 issues to consider when managing a severely immunocompromised host include the development of asympt
172 nostic for IFDs in a population of high-risk immunocompromised hosts including hematologic malignancy
173 recognized as a cause of systemic illness in immunocompromised hosts, including relapsing bacteremia
174 rtant cause of life-threatening pneumonia in immunocompromised hosts, including those with AIDS.
175 icant cause of morbidity and mortality among immunocompromised hosts, including transplant recipients
178 f the underlying mechanisms and safety in an immunocompromised host is limited due to lack of a suita
181 nslocation across the intestinal tract in an immunocompromised host is substantially reduced after ph
182 s amebic encephalitis (GAE), an infection of immunocompromised hosts, is almost uniformly fatal.
188 ania: Leishmania superinfection is common in immunocompromised hosts, particularly those infected wit
190 e importance of considering this organism in immunocompromised hosts presenting with severe infection
191 related diseases in both immunocompetent and immunocompromised hosts, ranging from localized infectio
192 but causes various disease manifestations in immunocompromised hosts, ranging from mild mucosal infec
193 s is the result of replication in a severely immunocompromised host, rather than the direct cause of
198 a mammalian pathogen that infects and kills immunocompromised hosts such as cancer and AIDS patients
199 form (type III) commonly found in tumors of immunocompromised hosts, suggesting that immune pressure
200 life-threatening malignancies in elderly and immunocompromised hosts, suggesting tight control of the
201 ction of genetically modified cells by these immunocompromised hosts suggests that strategies to rend
202 ciated with a high oncoprotein expression in immunocompromised hosts, suggests that this part of the
203 atinib treatment in both immunocompetent and immunocompromised hosts, T-cell immunity was essential f
204 disease, or cause more severe disease in the immunocompromised host than in the immunocompetent host.
205 rus 2 (SARS-CoV-2) infection lasts longer in immunocompromised hosts than in immunocompetent patients
206 is an emerging devastating infection in the immunocompromised host that is treated with corticostero
210 tant in certain patient populations, such as immunocompromised hosts, the critically ill, or individu
211 dorferi antibody had not yet appeared, or in immunocompromised hosts, the MIT compared favorably to c
215 l clinical manifestations in both normal and immunocompromised hosts; this agent is the most frequent
216 econdly, antibiotic treatment failure in the immunocompromised host was shown to occur without clinic
217 n KSHV-specific immune responses within this immunocompromised host, we implanted NOD/SCID mice with
218 investigate the interplay of viruses with an immunocompromised host, we performed functional genomics
219 mocystis jirovecii is a serious infection in immunocompromised hosts which requires prompt diagnosis
220 ration of persistent virus replication in an immunocompromised host, which may have implications for
221 sease, causing drug treatment failure in the immunocompromised host while simultaneously increasing t
222 hronic anemia due to persistent infection in immunocompromised hosts who cannot produce neutralizing
226 e in humans and is generally associated with immunocompromised hosts with indwelling foreign bodies.
228 tophilia causes high-mortality infections in immunocompromised hosts with limited therapeutic options
229 diseases specific to the infected organs of immunocompromised hosts, with discontinuation of immunos
230 addition, because of an increasing number of immunocompromised hosts worldwide, the guideline address